论文部分内容阅读
米非司酮（Ｒｕ４８６）为一种新型的抗早孕药，与前列腺素（ＰＧ）配伍序贯用于早孕妇女的口服。为探讨该药在细胞遗传学方面的安全性，对３８名接受Ｒｕ４８６口服前后的外周血淋巴细胞的微核率作对比研究，对３８名服用Ｒｕ４８３后流出的胚胎绒毛与早孕吸引流产的胚胎绒毛作对比研究，观察分析各自的微核率。淋巴细胞用药前后的微核发生率分别为１．０２６‰，１．０５３‰，无显著性差异。绒毛细胞的微核率用药组与非用药组分别为：１．８９４‰、１．０５６‰，有显著性差异
Mifepristone (Ru486) is a new type of anti-conception drug, which is used orally in combination with prostaglandin (PG) for early pregnant women. In order to investigate the cytogenetics safety of the drug, 38 micronuclei of peripheral blood lymphocytes before and after Ru486 oral administration were compared. 38 embryos villus exuding from Ru483 and abortive embryo villus For comparative study, observe and analyze their respective micronucleus rate. The incidence of micronuclei before and after lymphocyte treatment were 1.026 ‰ and 1.053 ‰, respectively, with no significant difference. The micronucleus rate of villus cells in treatment group and non-treatment group were: 1.894 ‰, 1.056 ‰, with significant difference